A typical DSIP dosage protocol in research runs 100–300 mcg subcutaneously at night, often cycled for 5–10 days. Learn timing, storage, and safety facts.
A typical DSIP dosage protocol in research settings is 100 to 300 micrograms (mcg) injected subcutaneously, taken 30 to 60 minutes before sleep, usually in short cycles of roughly 5 to 10 days. DSIP, or delta sleep-inducing peptide, is a nine-amino-acid peptide first isolated from rabbit brains in 1977. It is not FDA-approved for human use in the United States, so everything below describes published research and commonly shared protocols rather than a clinical prescription.
What DSIP Is and What It Is Studied For
DSIP is a naturally occurring peptide found in the brain and in peripheral tissues. Early researchers believed it promoted slow-wave sleep, which is where the name comes from. Later work tied it to stress response, pain signaling, blood pressure, and substance withdrawal, but the studies were small and the results were mixed.
Most human data comes from European research in the 1980s that used intravenous DSIP in controlled settings. Modern interest is driven largely by self-experimenters tracking sleep quality, not by regulated clinical trials. DSIP is a research peptide with no approved medical use, no standard dose, and no long-term human safety data.
Typical DSIP Dosage Protocol Ranges
The ranges below show up repeatedly in research summaries and peptide write-ups. They are not official guidelines, and individual response can vary widely.
| Route | Range cited in research summaries | Typical timing | Practical notes |
|---|---|---|---|
| Subcutaneous injection | 100–300 mcg per dose | 30–60 minutes before bed | The most frequently described protocol |
| Subcutaneous (weight-based) | About 25–50 mcg per kg | At bedtime | Derived mainly from animal work; not validated in humans |
| Intranasal | Roughly 100–500 mcg total | At bedtime | Absorption is inconsistent and data are sparse |
| Intravenous | Used in early clinical studies | Varies by study | Research setting only; not a home protocol |
| Oral or sublingual | Not established | — | Digestive enzymes likely break the peptide down |
The DSIP injection dosage is the version most people encounter first, and the 100–300 mcg range is repeated in nearly every summary. No head-to-head study has compared these routes in humans, so no one can say one approach works better than another. Many people start at the bottom of the range and hold that dose for a full cycle before changing anything.
Timing, Frequency, and Cycle Length
Timing matters as much as the number on the syringe, because the goal is usually sleep onset.
- Dose 30 to 60 minutes before bed. Keep lights low and skip screens so the effect is easier to judge.
- Start low. Many protocols open at 100 mcg, then move to 200 or 300 mcg only if the first cycle produces nothing.
- Cycle instead of running it daily for months. A common pattern is 5 to 10 days on, then one to four weeks off.
- Try every-other-night dosing. Some people report the same sleep benefit with fewer injections.
- Track results. Note sleep latency, night wakings, and morning grogginess rather than relying on memory.
Tolerance is a theoretical concern with nightly use, though no one has measured it directly for DSIP. Breaks also make it easier to tell whether the peptide is doing anything at all or whether better sleep came from routine and expectation.
How to Evaluate DSIP Products Sold Online
Anyone who finds dsip for sale should treat unverified vials as unknown chemicals rather than medicine. A credible research supplier provides a third-party certificate of analysis for each batch.
- Third-party testing: look for HPLC purity data and mass spectrometry confirmation of the peptide sequence.
- Batch-specific COAs: a generic PDF from years ago does not describe the vial in your hand.
- Cold chain and storage: lyophilized powder should ship with cold packs and be stored at 2–8°C, or frozen for long-term storage.
- Labeling: legitimate sellers typically mark product "for research use only, not for human consumption."
- Reconstitution: use bacteriostatic water, refrigerate after mixing, and never shake the vial.
Price is a poor quality signal in this market. Counterfeit and underdosed vials are common, and a cheap product with no documentation carries real risk.
Safety, Side Effects, and Legal Status
Reported short-term effects include headache, nausea, dizziness, drowsiness, and occasional changes in blood pressure or heart rate. Because DSIP can cause sedation, driving or operating machinery after a dose is a bad idea. Anyone taking sedatives, sleep aids, or alcohol should assume additive effects.
There is no FDA-approved DSIP product, and the FDA has issued warnings about peptides marketed as supplements. DSIP is not a controlled substance in the US, but selling it as a drug or dietary supplement is not legal. Long-term human safety is unknown, and people who are pregnant, nursing, or managing a chronic condition should talk with a healthcare professional before considering it.
DSIP vs Other Peptides People Research
DSIP is usually discussed alongside other peptides, though the goals and schedules differ.
| Peptide | Primary research interest | Common route | Timing pattern |
|---|---|---|---|
| DSIP | Sleep architecture, stress response | Subcutaneous | Nightly, before bed |
| Epitalon | Sleep, circadian rhythm, aging markers | Subcutaneous or intranasal | Evening, often cycled |
| PT-141 (bremelanotide) | Sexual desire | Subcutaneous | As needed, about 45 minutes before activity |
| BPC-157 | Tissue repair, gut lining | Subcutaneous or oral | Often twice daily |
The pt 141 dosage for men is studied for libido rather than sleep, and it follows an as-needed schedule instead of a nightly one. Vyleesi side effects are documented in FDA labeling because bremelanotide completed controlled trials, which is not true for DSIP. Questions about epitalon dosage injection come up in the same sleep-and-longevity conversations, and researchers focused on recovery often compare notes on bpc-157 dosage per body weight instead.
Key Takeaways
- DSIP is not FDA-approved for human use in the United States.
- A commonly cited research protocol is 100 to 300 mcg subcutaneously, 30 to 60 minutes before bed.
- Most protocols cycle DSIP for 5 to 10 days followed by a break of one to four weeks.
- No clinical trial has established an effective human dose of DSIP.
- Third-party testing is the single most useful check when evaluating any supplier.
Frequently Asked Questions
What is a typical DSIP dosage?
Most research summaries describe 100 to 300 micrograms injected subcutaneously 30 to 60 minutes before bed. No clinical trial has confirmed an effective human dose, and DSIP is not FDA-approved, so these figures are a reference point rather than a medical recommendation. Anyone considering it should speak with a healthcare professional first.
How long should a DSIP cycle last?
Common protocols run 5 to 10 days on, followed by one to four weeks off, and some people dose every other night instead. Because DSIP has no established dosing schedule, cycle length is a matter of trial and observation rather than evidence. Longer continuous use has not been studied for safety.
Is DSIP legal to buy in the US?
DSIP is not a controlled substance, but it is also not an approved drug or dietary supplement. Suppliers typically sell it labeled for research use only, and selling it for human consumption is not legal. Importing it for personal use carries a risk of seizure by customs.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.